RS-0139

· RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RS-0139, covering 2026-03-11 to 2026-03-11. Get the full timeline:

Most recent: Clinical Trial Update: Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors [Phase 1]